This is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.